Literature DB >> 10072473

Metabolism of the stable nitroxyl radical 4-oxo-2,2,6, 6-tetramethylpiperidine-N-oxyl (TEMPONE).

C Kroll1, H H Borchert.   

Abstract

The formation of new metabolites of the stable nitroxyl radical 4-oxo-2,2,6,6-tetramethylpiperidine-N-oxyl (TEMPONE) inside the isolated perfused rat liver was examined. The paramagnetic 4-hydroxy derivative (TEMPOL) and the diamagnetic 1,4-dihydroxy derivative were found to be the major metabolites besides the well-known corresponding hydroxylamine of TEMPONE. No reoxidation of the hydroxyl group in the 4-position was observed. The conversion of nitroxides to the sterically hindered secondary amines remains speculative. A redox cycle of nitroxide and hydroxylamine including the secondary amines is discussed. For the first time the biotransformation of the stable nitroxyl radical TEMPONE detected by means of GC and GC-MS has been examined and new metabolites have been described, i.e. the newly discussed metabolites have to be considered for the interpretation of electron paramagnetic resonance (EPR), magnetic resonance imaging (MRI) and dynamic nuclear polarization (DNP) measurements on using the spin probe TEMPONE.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10072473     DOI: 10.1016/s0928-0987(98)00047-5

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  3 in total

Review 1.  Effects of tempol and redox-cycling nitroxides in models of oxidative stress.

Authors:  Christopher S Wilcox
Journal:  Pharmacol Ther       Date:  2010-02-11       Impact factor: 12.310

2.  Comparative Genotoxicity of TEMPO and 3 of Its Derivatives in Mouse Lymphoma Cells.

Authors:  Xiaoqing Guo; Ji-Eun Seo; Steven M Bryce; Jenna A Tan; Qiangen Wu; Stacey L Dial; Martha M Moore; Nan Mei
Journal:  Toxicol Sci       Date:  2018-05-01       Impact factor: 4.849

Review 3.  Chemistry and antihypertensive effects of tempol and other nitroxides.

Authors:  Christopher S Wilcox; Adam Pearlman
Journal:  Pharmacol Rev       Date:  2008-12       Impact factor: 25.468

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.